New compound as an mTOR inhibitor and its use
ES3078903T3Undetermined Publication Date: 2026-09-18MEDICINAL BIOCONVERGENCE RESEARCH CENTER (50 00) +1
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- ES2019792007T
- Authority / Receiving Office
- ES · ES
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-04-26
- Filing Date
- 2019-04-26
- Publication Date
- 2026-09-18
- Estimated Expiration
- 2039-04-26
AI Technical Summary
Technical Problem
Current treatments for brain diseases related to the mTOR pathway, such as epilepsy, Alzheimer's disease, and Parkinson's disease, are inadequate, particularly for drug-resistant cases, and there is a need for compounds that can effectively inhibit mTOR activity and cross the blood-brain barrier.
Method used
Development of novel compounds represented by Formula 1, which inhibit mTOR activity and possess high blood-brain barrier permeability, allowing for therapeutic effects on brain diseases associated with the mTOR pathway.
Benefits of technology
The compounds effectively inhibit mTOR activity, providing therapeutic benefits for brain diseases like epilepsy, Alzheimer's, and Parkinson's by crossing the blood-brain barrier, addressing the limitations of existing treatments.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 00000035_0000 
Figure 00000035_0001 
Figure 00000036_0000
Abstract
The present invention relates to a novel compound as an mTOR inhibitor and to a use thereof and, more specifically, to a novel compound represented by formula 1 exhibiting mTOR inhibitory activity and to a pharmaceutical composition comprising it as an active ingredient for preventing or treating brain diseases associated with an mTOR pathway.
Need to check novelty before this filing date? Find Prior Art